Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · October 27, 2022

Prognostic Value of Systemic Immune-Inflammation Index in Patients With mRCC Treated With TKIs

Scientific Reports


Additional Info

Scientific Reports
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Sci Rep 2022 Oct 03;12(1)16559, KB Yücel, E Yekedüz, S Karakaya, D Tural, İ Ertürk, C Erol, Ö Ercelep, NŞ Öztaş, Ç Arslan, G Uçar, A Küçükarda, ÖN Sever, S Kılıçkap, O Can, SC Yazgan, B Öksüzoğlu, N Karadurmuş, MA Şendur, Y Ürün

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading